Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Investor Presentation
Q2 FY25
Investor Presentation
Q2 FY22
Investor Presentation
Q2 FY21
Investor Presentation
Q1 FY21
Investor Presentation
Q4 FY20
Medicamen Biotech Ltd (MEDICAMEQ) is currently trading at 312.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Medicamen Biotech Limited (MBL) is a research-driven pharmaceutical company focusing on developing, manufacturing, and marketing finished dosage formulations globally. MBL has a strong presence in over 40 countries and is a key player in the Indian oncology segment with its own sales force and branding team. The company operates three advanced pharmaceutical manufacturing facilities in India, capable of producing a wide range of therapeutic categories. MBL has undertaken strategic expansions, including substantial investments in manufacturing infrastructure, to meet increasing demand in both domestic and international markets. The acquisition of OPAL Pharmaceuticals Pty Ltd enhanced MBL's capabilities and market reach, particularly in the oncology product line.
Over the past 52 weeks, Medicamen Biotech Ltd has traded between a low of ₹210.10 and a high of ₹454.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Medicamen Biotech Ltd has a market capitalization of approximately 387.29. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Medicamen Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 38.57 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 387.29 Cr, Medicamen Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Medicamen Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Medicamen Biotech Ltd is 38.57. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Medicamen Biotech Limited (MBL) is a research-driven pharmaceutical company focusing on developing, manufacturing, and marketing finished dosage formulations globally.
MBL has a strong presence in over 40 countries and is a key player in the Indian oncology segment with its own sales force and branding team.
The company operates three advanced pharmaceutical manufacturing facilities in India, capable of producing a wide range of therapeutic categories.
MBL has undertaken strategic expansions, including substantial investments in manufacturing infrastructure, to meet increasing demand in both domestic and international markets.
The acquisition of OPAL Pharmaceuticals Pty Ltd enhanced MBL's capabilities and market reach, particularly in the oncology product line.
Pharmaceuticals & Biotechnology
Pharmaceuticals
424 Cr
Low Risk
42.2
37.7
2.6
1.4
454.00
210.10
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
8
Neutral
1
Bullish
5
Bearish
8
Neutral
1
Bullish
37
Bearish
0
Neutral
0
Bullish
32
Bearish
8
Neutral
1
Bullish
5
Bearish
8
Neutral
1
Bullish
5
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
376.85 | 449 Cr | 66.76 | 5.37 | 0.00 | 5.14 | 6.71 | 7.66 | ||
1497.20 | 438 Cr | 28.73 | 2.05 | 0.10 | 8.11 | 9.76 | 3.36 | ||
283.00 | 432 Cr | 35.58 | 3.57 | 0.00 | 10.04 | 16.02 | 8.12 | ||
312.55 | 387 Cr | 38.57 | 1.41 | 0.35 | 3.50 | 4.79 | 2.70 | ||
77.30 | 344 Cr | 35.32 | 1.01 | 0.00 | 4.41 | 5.15 | 4.28 | ||
289.55 | 344 Cr | 15.91 | 3.40 | 0.00 | 18.97 | 18.05 | 8.16 | ||
35.25 | 328 Cr | 23.77 | 4.35 | 0.00 | 17.38 | 20.98 | 9.01 | ||
| Median: 7 Co. | — | 289.55 | 387 Cr | 35.32 | 3.40 | 0.00 | 8.11 | 9.76 | 7.66 |
